

7:00 AM

Research & Clinical Care Symposium: Living with SMA: Considering Patients' Perspectives and the Evolving Landscape , Sponsored by Novartis

Track A: Clinical Care Session		
Time	Abstract Number	Presentation Title
8:30 AM		WELCOME AND CURE SMA UPDATE
		Mary Schroth, MD, Chief Medical Officer, Cure SMA
8:50 AM	А	HAVING A PLAN OF ATTACK – OUTPATIENT AND INPATIENT ESCALATION OF CARE DURING AN ACUTE ILLNESS AT HOME AND AWAY
		Hank Mayer, MD, Robert Graham, MD, Allyson Henkel, SMA Parent, Cure SMA Board Member
9:50 AM	В	ORTHOPEDIC MANAGEMENT DISCUSSION
		Moderator: Luca Labianca, MD
		EFFECT OF SCOLIOSIS ON PULMONARY FUNCTION IN SPINAL MUSCLE ATROPHY (SMA)
		Brian Snyder, MD, PhD
		TRAJECTORIES OF LOWER LIMB JOINT MOBILITY IN SMA; HIP EXTENSION MATTERS.
		Elizabeth Harding, PT, EdD
10:30 AM		BREAK
10:50 AM	С	A DISCUSSION ON GENITOURINARY ISSUES
		Angelena Edwards, MD, Douglas Storm, MD

Track B: Research Meeting		
Time	Abstract	Presentation Title
	Number	
8:30 AM		WELCOME
		Jackie Glascock, PhD, Chief Scientific Officer, Cure
		SMA
		Genetic Modifiers of Disease
		Moderator: Rashmi Kothary, PhD
8:45 AM	1	A SYNAPTIC CHAPERONE MODIFIES THE SMA
		PHENOTYPE IN THE SMN2B/- MOUSE MODEL OF
		THE DISEASE
		Narendra Nath Jha, PhD
9:05 AM	2	DETERMINING THE ROLE OF SARM1-MEDIATED
		AXON DEGENERATION IN SMA
		Madeline Denton, BS
9:25 AM	3	DLC1-I1 RESCUES MOTOR NEURONS IN SPINAL
		MUSCULAR ATROPHY BY ENHANCING SMN2
		SPLICING AND AXON GROWTH, OFFERING A
		NOVEL THERAPEUTIC STRATEGY
0.45.414		Tianyuan Shi, PhD
9:45 AM	4	IDENTIFICATION OF KIF5A AS A KEY FACTOR
		LINKING AXONAL PATHOLOGY IN SMA AND ALS
40.05		Tetsuya Akiyama, MD, PhD
10:05 AM		BREAK
		Gene Expression Changes & Transcript Diversity
		in SMA
		Moderator: Arthur Burghes, PhD
10:35	5	DIRECT RNA NANOPORE SEQUENCING
AM		REVEALS EXTENSIVE TRANSCRIPT ISOFORM
		DIVERSITY IN CONTROL AND SMA HUMAN IPSC
		DERIVED MOTOR NEURONS
		Stephen Brown, BS
10:55	6	LONG-READ SEQUENCING REVEALS NOVEL
AM		INSIGHTS INTO SMN LOCUS COMPLEXITY IN
		SMA
44.4-		Ewout Groen, PhD
11:15	7	COMPREHENSIVE SPATIAL TRANSCRIPTOME
AM		ANALYSIS OF SPINAL CORD AND
		SURROUNDING TISSUES IN NORMAL AND SMA
		MODEL MICE
11.05		Elliot Androphy, MD  IDENTIFICATION OF EARLY SYMPTOMATIC
11:35	8	
AM		GENE EXPRESSION CHANGES IN MOTOR
		NEURONS IN A LARGE ANIMAL MODEL OF MOTOR NEURON DISEASE
		Megan Baird, PhD

12:00 PM **LUNCH** 



	Abstract	Clinical CME Content Provided
	Abstract	
	, 1.00 1.0.01	
	Number	
		NEUROCOGNITION & SMA
		MODERATOR: JULIE PARSONS, MD
1:00 PM	9	INVESTIGATING THE DEVELOPMENTAL EXPRESSION OF SMN IN THE BRAIN IN A MOUSE M
		SPINAL MUSCULAR ATROPHY
		Charalambos Demetriou, PhD
1:20 PM	10	PANEL DISCUSSION: Uncovering Cognitive Implications in Spinal Muscular Atrophy:
		Research Gaps, Clinical Insights, and Future Directions
		Sarah Wright, DO, Eduardo Tizzano, MD, PhD, Gretchen Weatherly, PhD, LP
2:20 PM		BREAK
		UNDERSTANDING BULBAR FUNCTION: IMPACTS OF DISEASE AND TREATMENT IN MICE &
		MAN
		Moderator: Katherine Klinger, PhD
2:40 PM	11	CREATING HUMAN HINDBRAIN MOTOR NEURONS: A PLATFORM TO MODEL BULBAR
		SYMPTOMS IN SMA
		Kyle Loh, PhD
3:00 PM	12	DEFECTS OF SENSORY-MOTOR CIRCUITS - CONTROLLING FACIAL MUSCLES - MAY
		PROVIDE MECHANISTIC INSIGHTS IN SUCKLING AND MASTICATORY BEHAVIORAL
		DEFICITS IN SMA MICE
		Danny Florez-Paz, PhD
3:20 PM	13	DIFFERENCES IN SWALLOWING PHYSIOLOGY BETWEEN PRE- AND POST-
		SYMPTOMATICALLY TREATED PATIENTS WITH SMA
		Katlyn McGrattan, PhD
3:40 PM	14	ENHANCING BULBAR ASSESSMENT IN SPINAL MUSCULAR ATROPHY: A RASCH ANALYSIS
		OF THE INTERNATIONAL BULBAR ASSESSMENT TOOL (IBAT) PILOT STUDY
		Sally Dunaway Young, PT, DPT
4:30 PM		POSTER SESSION A: ODD NUMBERED POSTERS PRESENTED



	Abstract Number	<del></del> _
7:00 AM	- Tumbor	RESEARCH & CLINICAL CARE SYMPOSIUM: AN EVOLVING TREATMENT FOR SMA:
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		DISCOVER A NEW FORMULATION AND THE LATEST CLINICAL RESULTS ACROSS SMA
		TYPES AND AGE GROUPS
		Sponsored by Genentech
		NEURODEVELOPMENTAL DEFICITS, NEURODEGENERATION, AND CAPACITY FOR
		REGENERATION AFTER TREATMENT IN SMA
		Moderator: Charlotte Sumner, MD
8:30 AM	15	ABERRANT ANGIOGENESIS, BLOOD-SPINAL CORD BARRIER COMPROMISE, AND
0.007		NEUROINFLAMMATION IN SEVERE SPINAL MUSCULAR ATROPHY PATIENT SPINAL CORD
		Hazel Allardyce, PhD
8:50 AM	16	PREMATURE DIFFERENTIATION OF MOTOR NEURON PROGENITORS RENDERS MOTOR
0.0071		NEURONS VULNERABLE IN SPINAL MUSCULAR ATROPHY
		Zeynep Dokuzluoğlu, MscR.
9:10 AM	17	PROFILE TIME COURSE OF MOTOR UNIT REGENERATION AND STABILITY FOLLOWING
3.1371		ADMINISTRATION OF SMN-UPREGULATING THERAPEUTICS
		Inga Partlova, MscR
		Phenotypic and Genotypic Considerations in SMA Treatment
		Moderator: Kathyrn Swoboda, MD
9:30 AM	18	SPINAL MUSCULAR ATROPHY AMONG U.S. HUTTERITES: PHENOTYPE VARIABILITY IN THE
0.007111	1.0	SETTING OF CONSERVED ANCESTRAL HAPLOTYPE AND 4 SMN2 COPIES
		Kathryn Swoboda, MD
9:50 AM	19	NOVEL SMN1 MUTATIONS IDENTIFIED BY NEWBORN SCREENING: THERAPEUTIC
0.0071		HURDLES AND FUNCTIONAL SOLUTIONS
		Brunhilde Wirth, PhD
10:10 AM		BREAK
10:30 AM		ADULTS LIVING WITH SMA: PANEL Q&A
10.50 AM		Panelists: Brad Nunemaker, Lyza Weisman, Carolyn Barrett
		Moderators: Lyndsay Murray, PhD
		Tom Crawford, MD
11:30 AM		LUNCH
11:45 PM		RESEARCH & CLINICAL CARE SYMPOSIUM: MUSCLE MATTERS, UNDERSTANDING THE
11.45 FM		ROLE OF MUSCLE IN SMA
		Sponsored by Scholar Rock
		Assessing the Adult Experience: Outcomes and Biomarkers
		Moderator: Stephen Kolb, MD, PhD
1.00 DM	20	
1:00 PM	20	EXPLORING QUANTITATIVE MUSCLE TESTING AMONG TREATED ADULTS WITH SPINAL
		MUSCULAR ATROPHY: A REAL-WORLD PERSPECTIVE
1.00 DN4	0.1	Constance de Monts, PT, DPT
1:20 PM	21	LONG-TERM MOTOR RESPONSES TO DISEASE-MODIFYING THERAPIES IN SPINAL
		MUSCULAR ATROPHY (SMA) ADULTS: A PROSPECTIVE STUDY
		Tina Duong, MPT, PhD



1:40 PM	22	LONGITUDINAL EVALUATION OF ADULT PATIENTS WITH TYPE 3 SMA WITH SPINAL CORD IMAGING AND MOTOR SCALES: IN SEARCH OF NEW BIOMARKERS
		Felipe Franco da Graça, MD
2:00 PM		BREAK
		Outcome Measures for Research and Clinical Care
		Moderator: Allison Ebert, PhD
2:20 PM	23	QUANTITATIVE DESCRIPTION OF MOVEMENT AND POSTURE IN INFANTS WITH SMA USING
		A WEARABLE SENSOR SUIT AND A MACHINE LEARNING ALGORITHM
		Jinseok Oh, PhD
2:40 PM	24	GAIT SPEED IN SMA: A KEY VITAL SIGN LINKED TO STRENGTH AND FATIGABILITY
		Carly Mueller, PT, DPT, PCS
3:00 PM	25	RASCH ANALYSIS OF THE SPINAL MUSCULAR ATROPHY PERSON-REPORTED OUTCOME
		MEASURE (SMA-PRO) MOBILITY DOMAIN IN CHILDREN AND ADULTS WITH SMA.
		Amy Pasternak, PT, DPT, PCS
3:20 PM	26	RETROSPECTIVE ASSESSMENT OF FEEDING AND NUTRITION AFTER 2 YEARS OF
		RISDIPLAM TREATMENT IN CHILDREN WITH TYPE 1 SMA USING A NOVEL SCALE
		Giovanni Baranello MD, PhD
4:00 PM		POSTER SESSION B: EVEN NUMBERED POSTERS PRESENTED
6:30 PM		MEET AND GREET WITH FAMILIES: FEATURING ANNUAL RELAY RACE



# Annual SMA Research & Clinical Care Meeting June 25<sup>th</sup>- June 27<sup>th</sup>, 2025

	Abstract Number	Friday June 27 <sup>th</sup> , 2025	
7:00 AM	774777207	RESEARCH & CLINICAL CARE SYMPOSIUM: ELEVATING EXPECTATIONS IN SMA	
		CARE: OPTIMIZING PATIENT OUTCOMES	
		Sponsored by Biogen	
8:30 AM		PODIUM POSTER HIGHLIGHTS	
		Moderator: Jackie Glascock, PhD	
		CLINICAL THERAPEUTIC DEVELOPMENT	
		Moderator: Adrian Krainer, PhD	
9:10 AM	27	FIRST-IN-HUMAN STUDY OF EPIDURAL SPINAL CORD STIMULATION IN INDIVIDUALS	
		WITH SPINAL MUSCULAR ATROPHY	
		Genis Prat-Ortega, PhD	
9:30 AM	28	PIERRE CLINICAL TRIAL: SAFETY AND PERFORMANCE OF THECAFLEX DRX™: AN	
		IMPLANTABLE INTRATHECAL CATHETER AND SUBCUTANEOUS PORT SYSTEM FOR	
		REPEATED INTRATHECAL DELIVERY OF NUSINERSEN	
		Kathrin Meyer, PhD	
9:50 AM	29	TALDEFGROBEP ALFA IN SPINAL MUSCULAR ATROPHY: RESULTS OF THE PHASE 3	
		RESILIENT STUDY	
		Lindsey Lair, MD	
10:10 AM	30	NURTURE STUDY: LONG-TERM BENEFITS OF NUSINERSEN IN PRESYMPTOMATIC	
		SPINAL MUSCULAR ATROPHY (SMA) OVER 8-YEARS OF FOLLOW-UP	
		Nancy L Kuntz, MD	
10:30 AM		BREAK	
11:00 AM	31	DEVOTE PART C RESULTS: EXPLORING HIGHER DOSES OF NUSINERSEN IN	
		NUSINERSEN-EXPERIENCED PARTICIPANTS WITH SPINAL MUSCULAR ATROPHY	
		Richard Finkel, MD	
11:20 AM	32	EFFICACY AND SAFETY OF APITEGROMAB IN INDIVIDUALS WITH TYPE 2 AND TYPE 3	
		SPINAL MUSCULAR ATROPHY EVALUATED IN THE PHASE 3 SAPPHIRE TRIAL	
		Basil T. Darras, MD	
11:40 AM	33	INTRATHECAL ONASEMNOGENE ABEPARVOVEC FOR PATIENTS WITH SPINAL	
		MUSCULAR ATROPHY: PHASE 3, RANDOMIZED, SHAM-CONTROLLED, DOUBLE-	
		BLIND STEER STUDY	
		Crystal M. Proud, MD	
12:00 PM	34	INTRATHECAL ONASEMNOGENE ABEPARVOVEC FOR TREATMENT-EXPERIENCED	
		PATIENTS WITH SPINAL MUSCULAR ATROPHY: PHASE 3B, OPEN-LABEL STRENGTH	
		Jennifer M. Kwon MD, MPH, FAAN	
12:20 PM		CLOSING REMARKS	
		Jackie Glascock, PhD, Chief Scientific Officer, Cure SMA	
12:30 PM		RESEARCH AND CLINICAL CARE MEETING ADJOURNS	
6:30 PM		FAMILY FRIENDLY RESEARCHER POSTER SESSION	